Compare PDO & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDO | OGN |
|---|---|---|
| Founded | 2020 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | 2020 |
| Metric | PDO | OGN |
|---|---|---|
| Price | $11.93 | $13.79 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 11.80% | 0.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ N/A | $14.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.51 | $5.69 |
| 52 Week High | $14.20 | $13.83 |
| Indicator | PDO | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 58.45 |
| Support Level | $11.51 | $13.46 |
| Resistance Level | $13.23 | N/A |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 50.00 | 57.69 |
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary objective is to generate current income, with capital appreciation as a secondary objective. It employs a flexible, multi-sector investment strategy across credit markets, investing in a wide range of income-producing debt securities. The fund actively adjusts allocations to capitalize on opportunities across different economic cycles and market conditions.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.